Understanding anticoagulation therapy for stroke prevention and atrial fbrillation

Natalie Schellack; Senior Lecturer; Heleen Esterhuizen; Gustav Schellack

Understanding anticoagulation therapy for stroke prevention and atrial fbrillation

Natalie Schellack
, Senior Lecturer
, Heleen Esterhuizen
, Gustav Schellack

Research output: Contribution to journal › Literature review › peer-review

2 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article. © Medpharm.

Original language	English
Pages (from-to)	13-19
Number of pages	7
Journal	SA Pharmaceutical Journal
Publication status	Published - 7 Oct 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{5a0d24008eca41d0b2f8ad25f007abd3,

title = "Understanding anticoagulation therapy for stroke prevention and atrial fbrillation",

abstract = "Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article. {\textcopyright} Medpharm.",

author = "Natalie Schellack and Senior Lecturer and Heleen Esterhuizen and Gustav Schellack",

year = "2013",

month = oct,

day = "7",

language = "English",

pages = "13--19",

journal = "SA Pharmaceutical Journal",

issn = "1015-1362",

publisher = "Medpharm Publications",

}

TY - JOUR

T1 - Understanding anticoagulation therapy for stroke prevention and atrial fbrillation

AU - Schellack, Natalie

AU - Lecturer, Senior

AU - Esterhuizen, Heleen

AU - Schellack, Gustav

PY - 2013/10/7

Y1 - 2013/10/7

N2 - Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article. © Medpharm.

AB - Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article. © Medpharm.

UR - https://www.scopus.com/pages/publications/84884851494

UR - https://www.scopus.com/pages/publications/84884851494#tab=citedBy

M3 - Literature review

SN - 1015-1362

SP - 13

EP - 19

JO - SA Pharmaceutical Journal

JF - SA Pharmaceutical Journal

ER -

Understanding anticoagulation therapy for stroke prevention and atrial fbrillation

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this